[1] Fu ZD, Cui JY. Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. Curr Pharmacol Rep, 2017 Jun; 3:101-113.
[2] Marshall Jc.The gut as a potential trigger of exercise-induced inflammtory responses. Can J Physiol Pharmacol, 1998; 76: 479-484.
[3] Seki E, Schnab B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol, 2012,590:447-458.
[4] Wang J, Wang Y, Zhang X, et al. Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients.Front Microbiol, 2017,8:2222.
[5] Lu H, Wu Z, Xu W, et al. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol, 2011,61:693-703.
[6] Ren YD, Ye ZS, Yang LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology, 2017,65: 1765-1768.
[7] Preveden T, Scarpellini E, Milic'N, et al. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol, 2017,11:813-819.
[8] Wei X, Yan X, Zou D, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach.BMC Gastroenterol, 2013, 13:175.
[9] Ferrere G, Wrzosek L, Cailleux F, et al. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. J Hepatol, 2017,66:806-815.
[10] Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut, 2016,65:830-839.
[11] Han SH, Suk KT, Kim DJ, et al. Effects of probiotics (cultured Lactobacillus subtilis/ Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol, 2015,27:1300-1306.
[12] Lanthier N, Stärkel P. Treatment of severe alcoholic hepatitis: past, present and future. Eur J Clin Invest, 2017,47:531-539.
[13] Betrapally NS, Gillevet PM, Bajaj JS. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? Gastroenterology, 2016,150: 1745-1755.
[14] Loomba R, Seguritan V, Li W, et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab, 2017,25:1054-1062.
[15] Roderburg C, Luedde T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut Microbes, 2014,5:441-445.
[16] Grat M, Wronka KM, Krasnod bski M, et al. Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis. Transplant Proc, 2016,48:1687-1691.
[17] Lin R, Zhou L, Zhang J, et al. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol, 2015,8:5153-5160.
[18] Cai W, Ran Y, Li Y, et al. Intestinal microbiome and permeability in patients with autoimmune hepatitis. Best Pract Res Clin Gastroenterol, 2017,31:669-673.
[19] Czaja AJ. Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis. Aliment Pharmacol Ther, 2017,46:920-937.
[20] Kwak DS, Jun DW, Seo JG, et al. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. Eur J Gastroenterol Hepatol, 2014,26:1353-1359. |
